BridgeMD
New treatment option for Cannabis Use Disorder
Official title SV2A Density Cannabis Use Disorder
ClinicalTrials.gov ID: NCT05472818
What this study is testing
What is [11C]APP311?
[11C]APP311 is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for cannabis use disorder.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The main purpose of this study is to determine whether hippocampal synaptic vesicle density estimated by hippocampal [11C]APP-311/[11C]UCB-J binding in individuals diagnosed with cannabis use disorder (CUDs) improves with at least 4 weeks of confirmed abstinence from cannabis, in comparison to healthy controls (HCs). Furthermore, any change in synaptic vesicle density will be placed in functional context by measuring verbal memory, which is sensitive to hippocampal function, before and after at least 4 weeks of confirmed abstinence.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75. Healthy volunteers may be eligible.
You may be able to join if
- CUD Participants
- Able to provide informed consent
- Male and female 18-75 years old
- Daily cannabis use
- Positive urine screen for cannabinoids and negative for all other drugs on
You likely can't join if
- Laboratory tests with clinically significant abnormalities or positive urine toxicology screen with exception of cannabinoids.
- Women with a positive pregnancy test or women who are lactating.
- Have implanted or embedded metal objects or fragments in the head or body that would present a risk during the MRI scanning procedure, or have worked...
- Have had exposure to ionizing radiation that in combination with the study tracer would result in a cumulative exposure that exceeds recommended...
- History of a bleeding disorder or are currently taking anticoagulants (such as Coumadin, Heparin, Pradaxa, Xarelto) people who have donated blood...
- Medications that could alter synaptic density and, therefore, confound the interpretation of study data.
See the full eligibility criteria
- CUD Participants
- Able to provide informed consent
- Male and female 18-75 years old
- Daily cannabis use
- Positive urine screen for cannabinoids and negative for all other drugs on
- Diagnosis of DSM-5 cannabis use disorder (≥ moderate, i.e., ≥ 4 [of 11] symptoms).
- Must express a willingness at screening to set a date to attempt to quit using cannabis.
- Physically healthy i.e., no clinically unstable medical conditions.
- For women of childbearing potential (WOCBP) and men, willingness to practice birth control and to inform study staff immediately if either they (for women) or their partner (for men) becomes pregnant.
- Additional criteria not disclosed here in order to minimize the risk of ineligible people enrolling in the study. CUD Participants
- Laboratory tests with clinically significant abnormalities or positive urine toxicology screen with exception of cannabinoids.
- Women with a positive pregnancy test or women who are lactating.
- Have implanted or embedded metal objects or fragments in the head or body that would present a risk during the MRI scanning procedure, or have worked with ferrous metals either as a vocation or hobby (for example, as a...
- Have had exposure to ionizing radiation that in combination with the study tracer would result in a cumulative exposure that exceeds recommended exposure limits.
- History of a bleeding disorder or are currently taking anticoagulants (such as Coumadin, Heparin, Pradaxa, Xarelto) people who have donated blood within 8 weeks of the present study
- Medications that could alter synaptic density and, therefore, confound the interpretation of study data.
- Additional criteria not disclosed here in order to minimize the risk of ineligible people enrolling in the study. Healthy Controls Inclusion Criteria:
- Willing and able to give voluntary written informed consent
- Male and Female people, age 18 to 75 years, inclusive
- BMI within 19 to 35 kg/m2, inclusive
- Must be in good health as determined by medical history, physical examination, ECG, serum/urine biochemistry, hematology, and serology tests.
- Negative urine drug screen
- If female, not pregnant or breastfeeding
- If female of childbearing potential, must agree to use an acceptable method of birth control, as determined by the principal investigator, for the duration of the study and up to one month after completion of PET scans.
- Able to read and write, able to communicate effectively with the investigator, and comply with all study requirements, restrictions, and directions of the clinic staff.
- Have arterial access sufficient to allow blood sampling as per the protocol. Healthy Controls Exclusion Criteria:
- History or presence of clinically significant and unstable respiratory, GI, renal, hepatic, pancreatic, hematological, neurological (including history of seizure), cardiovascular, psychiatric (including known addictive...
- Abnormal clinically significant laboratory or physical findings during screening
- History of a bleeding disorder or are currently taking anticoagulants (such as Coumadin, Heparin, Pradaxa, Xarelto)
- A condition that, in the opinion of the investigator, would prevent compliance with the study protocol.
- Medications that could alter synaptic density and, therefore, confound the interpretation of study data.
- MRI incompatible implants and other contraindications for MRI, such as pace-maker, artificial joints, non-removable body piercings, metal fragments in head and/or body, or history working with ferrous metals either as a...
- people who suffer from claustrophobia.
- Participation in other research studies involving ionizing radiation within one year of the PET scans that would cause the subject to exceed the yearly dose limits for healthy volunteers
- Additional criteria not disclosed here in order to minimize the risk of ineligible people enrolling in the study.
The study team makes the final eligibility decision.
Where it's taking place
- New Haven, Connecticut, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include New Haven, Connecticut, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.